483 related articles for article (PubMed ID: 25568071)
21. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
[TBL] [Abstract][Full Text] [Related]
22. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
Sullivan TJ; Truglio JJ; Boyne ME; Novichenok P; Zhang X; Stratton CF; Li HJ; Kaur T; Amin A; Johnson F; Slayden RA; Kisker C; Tonge PJ
ACS Chem Biol; 2006 Feb; 1(1):43-53. PubMed ID: 17163639
[TBL] [Abstract][Full Text] [Related]
23. High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations.
Machado D; Perdigão J; Ramos J; Couto I; Portugal I; Ritter C; Boettger EC; Viveiros M
J Antimicrob Chemother; 2013 Aug; 68(8):1728-32. PubMed ID: 23539241
[TBL] [Abstract][Full Text] [Related]
24. First triclosan-based macrocyclic inhibitors of InhA enzyme.
Rodriguez F; Saffon N; Sammartino JC; Degiacomi G; Pasca MR; Lherbet C
Bioorg Chem; 2020 Jan; 95():103498. PubMed ID: 31855823
[TBL] [Abstract][Full Text] [Related]
25. Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against
Dey R; Nandi S; Samadder A; Saxena A; Saxena AK
Curr Top Med Chem; 2020; 20(29):2662-2680. PubMed ID: 32885754
[TBL] [Abstract][Full Text] [Related]
26. Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions.
Vilchèze C; Baughn AD; Tufariello J; Leung LW; Kuo M; Basler CF; Alland D; Sacchettini JC; Freundlich JS; Jacobs WR
Antimicrob Agents Chemother; 2011 Aug; 55(8):3889-98. PubMed ID: 21628538
[TBL] [Abstract][Full Text] [Related]
27. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.
Rawat R; Whitty A; Tonge PJ
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13881-6. PubMed ID: 14623976
[TBL] [Abstract][Full Text] [Related]
28. Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor.
Martínez-Hoyos M; Perez-Herran E; Gulten G; Encinas L; Álvarez-Gómez D; Alvarez E; Ferrer-Bazaga S; García-Pérez A; Ortega F; Angulo-Barturen I; Rullas-Trincado J; Blanco Ruano D; Torres P; Castañeda P; Huss S; Fernández Menéndez R; González Del Valle S; Ballell L; Barros D; Modha S; Dhar N; Signorino-Gelo F; McKinney JD; García-Bustos JF; Lavandera JL; Sacchettini JC; Jimenez MS; Martín-Casabona N; Castro-Pichel J; Mendoza-Losana A
EBioMedicine; 2016 Jun; 8():291-301. PubMed ID: 27428438
[TBL] [Abstract][Full Text] [Related]
29. Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis.
Stec J; Vilchèze C; Lun S; Perryman AL; Wang X; Freundlich JS; Bishai W; Jacobs WR; Kozikowski AP
ChemMedChem; 2014 Nov; 9(11):2528-37. PubMed ID: 25165007
[TBL] [Abstract][Full Text] [Related]
30. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.
Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ
J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146
[TBL] [Abstract][Full Text] [Related]
31. Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.
Delaine T; Bernardes-Génisson V; Quémard A; Constant P; Meunier B; Bernadou J
Eur J Med Chem; 2010 Oct; 45(10):4554-61. PubMed ID: 20696503
[TBL] [Abstract][Full Text] [Related]
32. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
Saharan VD; Mahajan SS
Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
[TBL] [Abstract][Full Text] [Related]
33. Detection of mutations associated with isoniazid resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
Jagielski T; Bakuła Z; Roeske K; Kamiński M; Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z; Bielecki J
J Antimicrob Chemother; 2014 Sep; 69(9):2369-75. PubMed ID: 24855126
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis isolates from Xi'an, China.
Zhou A; Nawaz M; Duan Y; Moore JE; Millar BC; Xu J; Yao Y
Microb Drug Resist; 2011 Jun; 17(2):275-81. PubMed ID: 21388297
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents.
Menendez C; Gau S; Lherbet C; Rodriguez F; Inard C; Pasca MR; Baltas M
Eur J Med Chem; 2011 Nov; 46(11):5524-31. PubMed ID: 21944473
[TBL] [Abstract][Full Text] [Related]
36. Discovery of cofactor-specific, bactericidal Mycobacterium tuberculosis InhA inhibitors using DNA-encoded library technology.
Soutter HH; Centrella P; Clark MA; Cuozzo JW; Dumelin CE; Guie MA; Habeshian S; Keefe AD; Kennedy KM; Sigel EA; Troast DM; Zhang Y; Ferguson AD; Davies G; Stead ER; Breed J; Madhavapeddi P; Read JA
Proc Natl Acad Sci U S A; 2016 Dec; 113(49):E7880-E7889. PubMed ID: 27864515
[TBL] [Abstract][Full Text] [Related]
37. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.
Kruh NA; Rawat R; Ruzsicska BP; Tonge PJ
Protein Sci; 2007 Aug; 16(8):1617-27. PubMed ID: 17600151
[TBL] [Abstract][Full Text] [Related]
38. [GenoType MTBDR plus 1.0® for the detection of cross-resistance between isoniazide and ethionamide in isolates of multidrug-resistant Mycobacterium tuberculosis].
Rueda J; Realpe T; Mejía G; Zapata E; Robledo J
Biomedica; 2015; 35(4):541-8. PubMed ID: 26844443
[TBL] [Abstract][Full Text] [Related]
39. Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents.
Menendez C; Chollet A; Rodriguez F; Inard C; Pasca MR; Lherbet C; Baltas M
Eur J Med Chem; 2012 Jun; 52():275-83. PubMed ID: 22483635
[TBL] [Abstract][Full Text] [Related]
40. Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
Bioorg Med Chem; 2014 Nov; 22(21):6134-45. PubMed ID: 25282650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]